Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | CASP1 | P29466 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | GABRA1 | P14867 | 6/20 | 0.49 |
| ▸ | GABRG2 | P18507 | 6/20 | 0.49 |
| ▸ | GABRB3 | P28472 | 6/20 | 0.49 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.49 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11231466 | 0.87 | ALDH1A1 (0.69) | MAPTALDH1A1SMN1; SMN2TSHRCASP1 | |
| SCHEMBL11231463 | 0.87 | ALDH1A1 (0.69) | MAPTALDH1A1SMN1; SMN2TSHRCASP1 | |
| SCHEMBL10999586 | 0.83 | ALDH1A1 (0.63) | MAPTALDH1A1SMN1; SMN2TSHRCASP1 | |
| SCHEMBL6299219 | 0.82 | MAPT (0.61) | MAPTALDH1A1SMN1; SMN2TSHRCASP1 | |
| SCHEMBL3310055 | 0.80 | ALDH1A1 (0.59) | MAPTALDH1A1SMN1; SMN2TSHRCASP1 | |
| SCHEMBL3310049 | 0.80 | ALDH1A1 (0.59) | MAPTALDH1A1SMN1; SMN2TSHRCASP1 | |
| SCHEMBL3310052 | 0.80 | ALDH1A1 (0.59) | MAPTALDH1A1SMN1; SMN2TSHRCASP1 | |
| SCHEMBL30513965 | 0.79 | SMN1; SMN2 (0.61) | MAPTALDH1A1SMN1; SMN2TSHRCASP1 | |
| SCHEMBL1697502 | 0.79 | SMN1; SMN2 (0.61) | MAPTALDH1A1SMN1; SMN2TSHRCASP1 | |
| SCHEMBL322161 | 0.78 | TSHR (0.65) | MAPTALDH1A1SMN1; SMN2TSHRCASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6911469-B2 | Sulfonamide compounds and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-06-28 | — | — | US | disclosed |
| US-20020099212-A1 | For therapy of disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-07-25 | — | — | US | disclosed |
| US-6348474-B1 | COMPOUNDS AS ANTIDIABETIC AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-19 | — | — | US | disclosed |
| EP-0995742-A1 | SULFONAMIDE COMPOUNDS AND MEDICINAL USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099212-A1 | For therapy of disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity | PDE2A, PDE3A, PDE12 | MAPT 4591/4885ALDH1A1 570/4885SMN1; SMN2 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.